# Task #016 evidence gap analysis summary

**Genes evaluated:** 29,606  
**Unique EnsemblIDs:** 29,606  
**Validation-strategy entries:** 11  
**Scores, rankings, candidate selections, or therapeutic recommendations created:** No

## Status results

| Dimension | Status | Genes | Percent |
| --- | --- | --- | --- |
| Discovery evidence | MISSING | 6683 | 22.573127 |
| Discovery evidence | OBSERVED | 4871 | 16.452746 |
| Discovery evidence | PARTIAL | 18052 | 60.974127 |
| Mechanistic evidence | MISSING | 29606 | 100.000000 |
| Therapeutic development evidence | MISSING | 12664 | 42.775113 |
| Therapeutic development evidence | PARTIAL | 16942 | 57.224887 |
| Risk evidence | MISSING | 28708 | 96.966831 |
| Risk evidence | PARTIAL | 898 | 3.033169 |
| Evidence maturity | MISSING | 3936 | 13.294602 |
| Evidence maturity | PARTIAL | 25670 | 86.705398 |

## Project-wide gaps

Dedicated genetic, functional-dependency, perturbational, trial-level clinical-development, normal-tissue, essentiality, and broader toxicity evidence are missing for every current profile. These are project evidence gaps, not gene-level negative findings.

Because dedicated mechanistic evidence is absent, no gene is classified as having complete mechanistic characterization. Because clinical-development and multiple risk subdomains are absent, development and risk can be at most `PARTIAL` in this snapshot. Evidence maturity likewise describes structural interpretability and cannot be complete under the current coverage.

## Meaning of the future-evidence field

`recommended_future_evidence_type` identifies evidence classes that could reduce the documented uncertainty for a profile. It is not a target recommendation, does not select genes, and does not define an order in which genes should be investigated. Pipe-delimited values are a gap inventory, not a ranking.

## Validation strategy

The validation matrix links each major gap to an appropriate data-source class, the scientific question it could answer, the uncertainty categories it could reduce, dependency checks, and an interpretation boundary. It does not authorize retrieval, experiments, or target progression.

## Missingness boundary

`MISSING` means the current evidence profile lacks the required evidence class. It does not mean the underlying biological property is absent. In particular:

- no functional-dependency data does not imply lack of dependency;
- no compound/mechanism record does not prove undruggability;
- no trial-level evidence does not prove lack of therapeutic potential;
- no safety-liability record does not imply safety;
- no normal-tissue or essentiality evidence does not imply low translational risk.

## Important limitations

- Statuses describe evidence availability and bounded current claims, not target quality.
- Discovery `OBSERVED` requires effect-supported DE, returned LUAD association evidence, and no expression sign-conflict flag; it still does not establish causality.
- Development and risk statuses intentionally remain partial when only some subdomains are observed.
- The same source can contribute to several fields; Task #013/#014 dependencies must be reviewed before future aggregation.
- External evidence is temporally versioned and public-database coverage is incomplete.

## Validation

All frozen hashes matched. The integrated registry retained 29,606 unique EnsemblIDs and 14,064 U2 genes. Every gene retained five valid Task #014 claims, all 207,242 evidence records reconciled to their claims, claim missingness/uncertainty states remained consistent, output order was preserved, and no numerical score or ranking field was generated.
